6ML.STU Molecular Partners AG
- Market cap
- -
- P/E
- -
- P/B
- 2.19x
- ROE
- -101.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 6ML.STU undervalued?
Graham numberThe Graham number of Molecular Partners AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Molecular Partners AG fundamental analysis
No fundamental analysis for Molecular Partners AG yet.
Molecular Partners AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
Molecular Partners AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Molecular Partners AG annual financial statements (CHF; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 10.4M | 14.3M | 9.34M | 9.33M | 190M | 7.04M | 4.97M | 0.00 | 0.00 |
| Gross Profit | -5.25M | - | - | - | - | - | - | - | - |
| Operating Income | -37.4M | -47.4M | -58.3M | -63.4M | 117M | -61.1M | -61.2M | -55.4M | -52.1M |
| EBITDA | -36.5M | -33.8M | -59.6M | -60.7M | 121M | -59.5M | -51.6M | -59.5M | -49.2M |
| Net Income | -37.0M | -48.3M | -62.8M | -63.8M | 118M | -62.0M | -54.0M | -61.7M | -51.2M |
| EPS | -1.74 | -2.24 | -2.15 | -1.98 | 3.27 | -1.89 | -1.47 | -1.65 | -1.34 |
| Balance Sheet | |||||||||
| Total Assets | 155M | 105M | 188M | 173M | 262M | 198M | 159M | 102M | 64.5M |
| Total Liabilities | 63.5M | 50.8M | 80.3M | 65.4M | 27.1M | 21.9M | 16.9M | 21.8M | 13.9M |
| Shareholders' Equity | 91.7M | 54.1M | 107M | 107M | 235M | 176M | 142M | 80.3M | 50.7M |
| Cash & Short-term Investments | 99.0M | 75.7M | 134M | 71.8M | 87.9M | 67.3M | 63.9M | 82.7M | 57.5M |
| Cash Flow | |||||||||
| Operating Cash Flow | -42.5M | -56.1M | -29.0M | -91.0M | 119M | -59.0M | -59.2M | -51.3M | -47.4M |
| Capital Expenditure | 867K | 2.15M | 1.68M | 1.31M | 1.42M | 808K | 723K | 714K | 0.00 |
| Free Cash Flow | -43.3M | -58.3M | -30.7M | -92.3M | 117M | -59.8M | -60.0M | -52.0M | -47.4M |
| Ratios | |||||||||
| ROE | -40.4% | -89.2% | -58.5% | -59.5% | 50.1% | -35.1% | -38.2% | -76.7% | -101.1% |
| ROA | -23.9% | -46.0% | -33.5% | -36.9% | 44.9% | -31.2% | -34.1% | -60.4% | -79.4% |
| Net Profit Margin | -357.7% | -336.6% | -671.7% | -683.7% | 62.2% | -880.7% | -1,087.4% | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Molecular Partners AG dividends
Molecular Partners AG has not paid dividends in the last 8 fiscal years.
Who owns Molecular Partners AG
Ownership data of Molecular Partners AG is not available yet.
Molecular Partners AG company profile
- Company name
- Molecular Partners AG
- Ticker
- 6ML.STU
- ISIN
- CH0256379097
- Exchange
- Stuttgart Exchange
- Sector
- -
- Industry
- -
- Fiscal year end
- December
- Address
- Website
- -